HappyLibrarian,
Not really. The German action should have been perceived as positive had it been able to be fully explained without creating greater vulnerabilities to trial data integrity and even worse short attacks because of longs abandoning due to knowing time cost constraints.
Mr. Woodford had his own plans it seems and when those plans failed so did additional funding. This coupled with the need for closed system manufacturing for L as a top priority and getting a better handle on treatment induced pseudoprogression, which caused additional treatment with Direct to stop in the Phase 1 trial, were the majority contributing factors along with patents and biomarker correlations being improved upon along the way before moving into additional trials. “The process”, designed to maintain the status quo, just takes too long when a safe and effective treatment has been discovered. Best wishes.
Market Data 
Markets 
AI
